SCHEMBL5519786

SCHEMBL5519786

O=C(NCc1ccc(F)cc1)c1cc(-c2cccs2)nc(O)c1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
ERCC1 P07992 1/20 0.57
FEN1 P39748 1/20 0.57
ERCC4 Q92889 1/20 0.57
KDM4E B2RXH2 3/20 0.54
HPGDS O60760 2/20 0.49
ADORA2A P29274 1/20 0.49
MAPT P10636 2/20 0.48
GAA P10253 2/20 0.48
HPGD P15428 2/20 0.48
GLA P06280 1/20 0.48
THRB P10828 1/20 0.48
RXFP1 Q9HBX9 1/20 0.47
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.46
ATM Q13315 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5117933 0.79 ERCC1 (0.66) ALDH1A1MEN1KMT2AERCC1FEN1
SCHEMBL5520239 0.79 GLA (0.58) ALDH1A1MEN1KMT2AKDM4EHPGDS
SCHEMBL6373095 0.79 ERCC1 (0.60) ALDH1A1MEN1KMT2AERCC1FEN1
SCHEMBL5517463 0.78 TDP1 (0.54) ALDH1A1MEN1KMT2AGAARXFP1
SCHEMBL5517421 0.78 L3MBTL1 (0.45) ALDH1A1KMT2AKDM4EGAAGLA
SCHEMBL14470263 0.77 GAA (0.44) ALDH1A1KMT2AKDM4EMAPTGAA
SCHEMBL5530855 0.76 KMT2A (0.56) ALDH1A1KMT2AKDM4EADORA2AMAPT
SCHEMBL28765094 0.75 RXFP1 (0.48) ALDH1A1MEN1KMT2AKDM4EADORA2A
SCHEMBL5521786 0.75 HTT (0.48) ALDH1A1MEN1KMT2AKDM4EMAPT
SCHEMBL6373223 0.74 ERCC1 (0.63) ALDH1A1MEN1KMT2AERCC1FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101014571-A N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as HIV integrase inhibitors MERCK & CO INC (US) 2007-08-08 CN claimed
US-20070155744-A1 N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P, ANGELETTI S.P.A. (IT) 2007-07-05 US claimed
EP-1713773-A2 N-BENZYL-3,4-DIHYROXYPYRIDINE-2-CARBOXAMIDE AND N-BENZYL-2,3-DIHYDROXYPYRIDINE-4-CARBOXAMIDE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-10-25 EP claimed
WO-2005074513-A2 N-BENZYL-3,4-DIHYROXYPYRIDINE-2-CARBOXAMIDE AND N-BENZYL-2,3-DIHYDROXYPYRIDINE-4-CARBOXAMIDE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-08-18 WO claimed
CN-101014571-A N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as HIV integrase inhibitors MERCK & CO INC (US) 2007-08-08 CN disclosed
US-20070155744-A1 N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P, ANGELETTI S.P.A. (IT) 2007-07-05 US disclosed
US-20070155744-A1 N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P, ANGELETTI S.P.A. (IT) 2007-07-05 US disclosed
EP-1713773-A2 N-BENZYL-3,4-DIHYROXYPYRIDINE-2-CARBOXAMIDE AND N-BENZYL-2,3-DIHYDROXYPYRIDINE-4-CARBOXAMIDE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-10-25 EP disclosed
WO-2005074513-A2 N-BENZYL-3,4-DIHYROXYPYRIDINE-2-CARBOXAMIDE AND N-BENZYL-2,3-DIHYDROXYPYRIDINE-4-CARBOXAMIDE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155744-A1 N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors DUT, NQO2, TYMP ALDH1A1 2368/4885MEN1 4433/4885KMT2A 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.